Hero - Delta-8 vs CBD
Home/Compare/Delta-8 vs CBD

Delta-8 vs CBD: One Is Intoxicating and EFSA Rates It Equal to THC

CBD is not intoxicating. Delta-8 THC is, through the same receptor mechanism as regular THC. It is often sold as a gentler, legal, half-strength alternative. A 2025 head-to-head human trial found that doubling the delta-8 dose made it indistinguishable from delta-9 on every measure, and EFSA’s 2025 risk assessment assigned delta-8 a relative potency factor of one, meaning it treats the two as equivalent.

Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic
Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic

At a glance

Property
Delta-8
CBD
Intoxicating
Yes, via CB1 partial agonism
No
CB1 affinity
Ki 36 nM against delta-9's 20 nM in the same assay. 1.8 to 7.7 times weaker depending on study
No meaningful activation
CB2 affinity
Around 50 nM, essentially identical to delta-9
Ki 240 nM, low efficacy
Where it comes from
Acid-catalysed conversion, usually from CBD. Rarely found in natural hemp
Extracted from hemp, from CBDA
Oral bioavailability
Around 9 percent
Never measured in humans
EFSA relative potency vs delta-9
1
Not applicable
Drug test
Yes, it will show
Usually not, but full spectrum carries trace THC
Approved medicine
None
Epidiolex
Status from 12 Nov 2026
Likely excluded as a synthesized cannabinoid
Not the target of the change

Delta-8 is manufactured, not harvested

This matters more than it sounds.

Delta-8 THC is a structural isomer of delta-9 THC, with the double bond in a different position. It is the more thermodynamically stable of the two. Crucially, it is not a decarboxylation product, so unlike THC there is no acid precursor the plant makes in quantity.

In natural hemp, delta-8 is undetected in most samples and appears only sporadically, plausibly as an analytical artefact or a processing by-product, according to EFSA’s 2025 assessment.

Commercially, delta-8 is made by treating CBD with acid, which cyclises it. A 1981 study showed acid treatment of pure delta-9 THC produced a mixture of 97 percent delta-8 and 3 percent delta-9. That is a chemical conversion carried out in a facility, not an extraction.

The quality consequence is documented. A 2022 analysis of ten commercial delta-8 products found impurities in concentrations far beyond what the certificates of analysis declared. The acid-catalysed conversion generates by-products whose toxicology nobody has studied.

CBD is extracted rather than converted. It is present in hemp in quantity, as CBDA, and the process removes it from the plant rather than building it in a reactor.

The potency claim, tested properly

Delta-8
Delta-8 is a CB1 partial agonist, the same mechanism as delta-9. Its CB1 affinity is 1.8 to 7.7 times weaker depending on the study; in the single assay that measured both, 36 nM against delta-9's 20 nM.
At equal 20 mg doses, delta-8 produced significantly weaker drug effects, less impairment and a smaller heart rate rise than delta-9.
At 40 mg delta-8 against 20 mg delta-9, there were no pharmacodynamic differences at all. Doubling the dose completely erased the gap.
Both 20 mg and 40 mg delta-8 produced drug-liking comparable to 20 mg delta-9, meaning comparable misuse potential.
Delta-8 also has higher oral bioavailability than delta-9, around 9 percent against 6 percent, with higher peak concentration and total exposure at the same dose.
CBD
CBD does not activate CB1 and is not intoxicating.
Its clinical record is mixed but substantial: strong evidence in three rare epilepsy syndromes at doses of roughly 700 to 1,400 mg a day, largely negative evidence in pain across 16 randomized trials, and a modest anxiety signal at high acute doses.

The marketing position is that delta-8 is roughly half-strength THC, and therefore a milder experience. The pharmacology gives that claim partial support and then takes most of it back.

Then a 2025 study in Drug and Alcohol Dependence tested it head to head. Nineteen healthy adults with no recent cannabinoid exposure, double-blind crossover, brownies containing 10, 20 or 40 mg delta-8, 20 mg delta-9, or placebo. The findings:

EFSA’s 2025 assessment worked from that trial and derived a relative potency point estimate of 1.0 to 1.4, set a relative potency factor of 1, and applied the same acute reference dose to the sum of delta-8 and delta-9 THC.

The trial authors flagged why this matters: people who use these products generally perceive delta-8 as less harmful and less intoxicating than delta-9.

The two are not really alternatives to each other. One is an intoxicant and one is not.

Still weighing up the options? See CBD vs THC or THCa vs CBD. For more background, read our guide on whether CBD shows up on a drug test. Endoca products related to this comparison: THC-free CBD.

How Endoca tests for this

We do not make delta-8 products, and this page is the explanation rather than a competitive swipe. Delta-8 requires converting CBD in an acid reaction, and published analysis shows commercial products carrying undeclared by-products. We extract cannabinoids that the plant produces and publish what the lab finds. That is a different business, and we would rather be clear about which one we are in.

Frequently asked questions

They are not comparable in that way. Delta-8 is intoxicating and CBD is not.

At equal doses it produces weaker effects. Double the dose and the difference disappears entirely, and EFSA treats them as equipotent for risk assessment.

Yes. Standard tests detect THC metabolites and do not distinguish the isomers reliably.

It is barely present in natural hemp. Commercial delta-8 is manufactured from CBD.

CBD inhibits the enzymes that clear THC compounds, so combining them may increase rather than reduce intoxication.

Yes. Delta-8 THC activates the CB1 receptor and is intoxicating. CBD is not, which is the core difference between the two.

Not necessarily. Many regulators treat delta-8 as a controlled THC and several countries and US states restrict or ban it, even where hemp CBD is allowed. Check the rules for your location before buying.

References

01

Zamarripa CA et al. Pharmacodynamic comparison of delta-8-THC and delta-9-THC. Drug Alcohol Depend 2025;272:112676.

02

EFSA CONTAM Panel. Health-based guidance value for delta-8-THC. EFSA Journal 2025;23(11):e9735.

03

Tagen M, Klumpers LE. Review of delta-8-THC. Br J Pharmacol 2022;179:3915-3933.

04

Ray SD et al. Analysis of commercial delta-8-THC products. Molecules 2022;27:6924.

05

Congressional Research Service. Report R48637, 20 August 2025.

06

Congressional Research Service. Legal Sidebar LSB11381, 22 December 2025.

Last reviewed 1 September 2026.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.